Phenotype standardization for statin-induced myotoxicity

A. Alfirevic (Lead / Corresponding author), D. Neely, J. Armitage, H. Chinoy, R. G. Cooper, R. Laaksonen, D. F. Carr, K. M. Bloch, J. Fahy, A. Hanson, Q. Y. Yue, M. Wadelius, A. H. Maitland-van Der Zee, D. Voora, B. M. Psaty, C. N. A. Palmer, M. Pirmohamed

    Research output: Contribution to journalArticlepeer-review

    167 Citations (Scopus)
    213 Downloads (Pure)


    Statins are widely used lipid-lowering drugs that are effective in reducing cardiovascular disease risk. Although they are generally well tolerated, they can cause muscle toxicity, which can lead to severe rhabdomyolysis. Research in this area has been hampered to some extent by the lack of standardized nomenclature and phenotypic definitions. We have used numerical and descriptive classifications and developed an algorithm to define statin-related myotoxicity phenotypes, including myalgia, myopathy, rhabdomyolysis, and necrotizing autoimmune myopathy.

    Original languageEnglish
    Pages (from-to)470-476
    Number of pages7
    JournalClinical Pharmacology & Therapeutics
    Issue number4
    Early online date4 Jun 2014
    Publication statusPublished - Oct 2014

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Pharmacology


    Dive into the research topics of 'Phenotype standardization for statin-induced myotoxicity'. Together they form a unique fingerprint.

    Cite this